Cargando…

Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer

BACKGROUND: The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelissier, Aurélie, Roulot, Aurélie, Guéry, Béatrice, Bonneau, Claire, Bellet, Dominique, Rouzier, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039904/
https://www.ncbi.nlm.nih.gov/pubmed/27677313
http://dx.doi.org/10.1186/s13048-016-0270-7
_version_ 1782456145761271808
author Pelissier, Aurélie
Roulot, Aurélie
Guéry, Béatrice
Bonneau, Claire
Bellet, Dominique
Rouzier, Roman
author_facet Pelissier, Aurélie
Roulot, Aurélie
Guéry, Béatrice
Bonneau, Claire
Bellet, Dominique
Rouzier, Roman
author_sort Pelissier, Aurélie
collection PubMed
description BACKGROUND: The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were included. RESULTS: Based on ROC curves analysis, CA125 ≤ 75 UI/ml and HE4 ≤ 252 pmol/L after the 3rd cycles of NAC, with a sensitivity of 93.7 % and a specificity of 92.3 % (PPV = 93.7 % and NPV = 92.3 %), offered the best combination for predicting optimal cytoreduction. In addition, the HE4 value of 115 pmol/L is the best cut-off level for identifying platinum-sensitive patients. CONCLUSIONS: The introduction of HE4 as a new tool for predicting platinum-sensitivity and interval optimal cytoreduction is promising.
format Online
Article
Text
id pubmed-5039904
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50399042016-10-05 Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer Pelissier, Aurélie Roulot, Aurélie Guéry, Béatrice Bonneau, Claire Bellet, Dominique Rouzier, Roman J Ovarian Res Research BACKGROUND: The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were included. RESULTS: Based on ROC curves analysis, CA125 ≤ 75 UI/ml and HE4 ≤ 252 pmol/L after the 3rd cycles of NAC, with a sensitivity of 93.7 % and a specificity of 92.3 % (PPV = 93.7 % and NPV = 92.3 %), offered the best combination for predicting optimal cytoreduction. In addition, the HE4 value of 115 pmol/L is the best cut-off level for identifying platinum-sensitive patients. CONCLUSIONS: The introduction of HE4 as a new tool for predicting platinum-sensitivity and interval optimal cytoreduction is promising. BioMed Central 2016-09-27 /pmc/articles/PMC5039904/ /pubmed/27677313 http://dx.doi.org/10.1186/s13048-016-0270-7 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Pelissier, Aurélie
Roulot, Aurélie
Guéry, Béatrice
Bonneau, Claire
Bellet, Dominique
Rouzier, Roman
Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
title Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
title_full Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
title_fullStr Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
title_full_unstemmed Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
title_short Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
title_sort serum ca125 and he4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039904/
https://www.ncbi.nlm.nih.gov/pubmed/27677313
http://dx.doi.org/10.1186/s13048-016-0270-7
work_keys_str_mv AT pelissieraurelie serumca125andhe4levelsaspredictorsforoptimalintervalsurgeryandplatinumsensitivityafterneoadjuvantplatinumbasedchemotherapyinpatientswithadvancedepithelialovariancancer
AT roulotaurelie serumca125andhe4levelsaspredictorsforoptimalintervalsurgeryandplatinumsensitivityafterneoadjuvantplatinumbasedchemotherapyinpatientswithadvancedepithelialovariancancer
AT guerybeatrice serumca125andhe4levelsaspredictorsforoptimalintervalsurgeryandplatinumsensitivityafterneoadjuvantplatinumbasedchemotherapyinpatientswithadvancedepithelialovariancancer
AT bonneauclaire serumca125andhe4levelsaspredictorsforoptimalintervalsurgeryandplatinumsensitivityafterneoadjuvantplatinumbasedchemotherapyinpatientswithadvancedepithelialovariancancer
AT belletdominique serumca125andhe4levelsaspredictorsforoptimalintervalsurgeryandplatinumsensitivityafterneoadjuvantplatinumbasedchemotherapyinpatientswithadvancedepithelialovariancancer
AT rouzierroman serumca125andhe4levelsaspredictorsforoptimalintervalsurgeryandplatinumsensitivityafterneoadjuvantplatinumbasedchemotherapyinpatientswithadvancedepithelialovariancancer